Molecular and Clinical Assessment in the Treatment of AIDS Kaposi Sarcoma with Valproic Acid by Lechowicz, Maryjo et al.
Molecular and Clinical Assessment in the Treatment of AIDS
Kaposi’s Sarcoma with Valproic Acid
MARYJO LECHOWICZ1, DIRK P DITTMER2, JEANNETTE Y LEE3, SUSAN E KROWN4,
WILLIAM WACHSMAN5, DAVID ABOULAFIA6, BRUCE DEZUBE7, LEE RATNER8,
JONATHAN SAID9, and RICHARD F AMBINDER10
1Winship Cancer Institute, Emory University, Atlanta, GA
2Lineberger Comprehensive Cancer Center, Center for AIDS research, Department of Microbiology
and Immunology, University of North Carolina, Chapel Hill, NC
3Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR
4Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
5Department of Medicine, University of California, San Diego, CA
6Virginia Mason Cancer Center, Seattle, WA
7Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA
8Department of Medicine, Washington University St. Louis, St Louis, MO
9Department of Pathology, University of Southern California School of Medicine, Los Angeles, CA
10Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD
Abstract
The AIDS Malignancy Consortium (AMC) undertook a pilot trial of valproic acid (VA) in patients
with AIDS-associated Kaposi’s sarcoma (KS). Treatment was associated with low toxicity, but the
KS clinical response and KS herpesvirus lytic induction rates were not sufficiently high to meet pre-
defined criteria for efficacy.
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INTRODUCTION
Kaposi’s sarcoma (KS) is an AIDS-defining neoplasm that may occur even when HIV RNA
levels are effectively suppressed by antiretroviral therapy[1,2]. KS is consistently associated
with the KS herpesvirus (KSHV or HHV-8)[3]. In tumors, latent viral gene expression is
detected consistently, whereas lytic viral genes are infrequently expressed. Histone deacetylase
(HDAC) inhibitors are important laboratory tools for activating KSHV lytic cycle gene
expression[4]. Viral lytic induction in vivo might directly lead to death of latently-infected
tumor cells or lead to expression of antigenic viral proteins that would render tumor cells more
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susceptible to T cells. Valproic acid (VA), an agent used to treat seizure and mood disorders,
activates lytic gene expression in KSHV-infected cell lines[5].
VA has properties of a HDAC inhibitor[6] and the literature suggests a variety of possible
effects in AIDS-KS patients. VA has been variably reported to rescue replication-competent
HIV-1 from resting CD4+ T cells and thus reduce the size of the HIV latency reservoir[7,8].
Induction of KSHV lytic infection also raised concerns that VA treatment could lead to KS
progression or development of KS in seropositive patients without tumor[5]. With these
rationales and concerns in mind, the AIDS Malignancy Consortium (AMC) in conjunction
with the AIDS and Cancer Specimen Resource (ACSR) undertook a pilot clinical study to
determine the safety and efficacy of VA in AIDS-KS patients.
METHODS
Patients
Eligible patients had biopsy-confirmed KS and documented HIV infection. Patients with
visceral or rapidly progressive KS were excluded as were those with a Karnofsky performance
status <60 or life expectancy <3 months. Patients on antiretroviral therapy were required to be
on a stable regimen for ≥4 weeks before enrollment. Because VA and zidovudine have been
associated with lactic acidosis, patients with a history of lactic acidosis and those receiving
zidovudine-containing regimens were excluded[9].
Sample Size Estimation and Stopping Rule
We prospectively specified four criteria be met to conclude that VA was safe, effective and
likely to be working according to the hypothesized mechanism: a low toxicity-related
discontinuation rate (<35%), a low rate of accelerated KS progression (<10%), a high clinical
response rate (>30%), and a high rate of induction of lytic viral gene expression (>60%).
Eighteen patients were sufficient to evaluate these four measures. No adjustment for multiple
testing was made.
Study design and treatment
This was a prospective, open-label pilot study to determine the safety of VA in patients with
AIDS-KS and evaluate the effect of VA on KSHV gene expression. Secondary endpoints
included evaluation of the effects of VA on HIV and KSHV in blood and clinical response.
After giving written informed consent, patients received VA for 28 days followed by a 2-week
taper. VA (250mg capsules) was administered twice daily. The dose was escalated over the
first six days from 500mg to 1000mg. Thereafter dosing was adjusted to achieve the therapeutic
range established for epilepsy (50-100mg/liter). Although VA treatment ended after 6 weeks,
patients were monitored for 24 weeks or until KS progression.
Schedule of events
Clinical assessments, including history and physical examinations, tumor assessments,
complete blood count, serum electrolytes, renal and liver function tests were performed at
baseline, on days 8, 15, 29; and monthly thereafter. CD4 T-lymphocyte counts were obtained
at baseline. HIV-1 RNA was measured at baseline, on days 45-50, and every 3 months
thereafter. Tumor punch biopsies were obtained at baseline, and days 8 and 29. Plasma and
PBMC for KSHV copy number were obtained at baseline, days 8, 15, 29 and 1 month later.
Tumor assessments were performed at baseline, at days 8, 15, 29 and monthly thereafter.
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Assays for KSHV gene expression
Punch biopsy specimens (3mm) were snap frozen in liquid nitrogen for RNA studies or
formalin fixed for immunohistochemistry. Specimens forwarded to the ACSR were coded and
batched before transfer to laboratories for blinded evaluation. KSHV protein expression
(LANA, vIL6, ORF8.1, ORF59) was categorized as (-), (+/-), (+), (++), (+++) or non-evaluable
based on the number of positive staining cells and stain intensity. KSHV transcription was
profiled using real-time quantitative PCR as previously described[10]. RNA quality was
ascertained using an Agilent Bioanalyzer. Data were normalized to the mean of 3 housekeeping
mRNAs to yield dCT, a log-transformed measure of relative RNA abundance.
Assays for KSHV DNA
KSHV copy number in plasma and PBMC was assessed by real-time PCR as previously
described[11]. Blood was collected into heparin tubes, transported at ambient temperature and
processed within 30 hours. DNA was isolated using the QIAGEN Blood Kit (QIAGEN Inc.,
Valencia, CA).
Response criteria
Tumor assessments and grading of responses as complete, partial, stable or progression were
performed as previously described[12].
Toxicity
Adverse events were classified as possibly, probably or definitely related to VA, and their
severity was graded using the NCI Common Toxicity Criteria version 3.0.
Statistical Methods
The Wilcoxon signed rank test was used to evaluate changes from baseline for laboratory
correlates. The Spearman correlation coefficient was used to evaluate bivariate correlations.
RESULTS
Patients
Nineteen patients were enrolled. One patient withdrew before receiving treatment. The
remaining 18 patients completed the planned 28 days of therapy. All patients were men. At
entry, most were receiving antiretroviral therapy, had an undetectable HIV viral load, had
previously received treatment for KS, and had tumor-associated edema. Half of the patients
had ≥50 lesions. Patient and tumor characteristics are summarized in Table 1.
Toxicity
The only adverse event that occurred in more than one patient was mild diarrhea, which
occurred in two patients. No patient discontinued treatment due to toxicity.
Clinical outcomes
One patient achieved a partial response that persisted without further intervention at last follow-
up 5 months after therapy. Two other patients achieved partial responses 4 months and 6 months
post-treatment without any intervening KS treatment. One patient showed an approximately
30% increase in the size of marker lesions in the 4 weeks of therapy, while at the same time
the total number of lesions decreased from 128 to 99. No patients developed rapid KS
progression.
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KSHV gene expression in tumor biopsies
Viral gene expression in tumor biopsies was assessed by immunohistochemical staining. Latent
(LANA) and lytic (vIL6, ORF8.1, ORF59) antigens were detected in most specimens at
baseline and following VA treatment (Supplementary Table 2). Paired t-tests showed no
significant differences in expression between baseline and either day 8 or day 29 for any of
these antigens, Using real-time QPCR to assess KSHV mRNAs in biopsies, significant changes
were not detected by t-test. We hypothesized that higher VA trough levels might be associated
with more robust lytic induction. Although we saw no correlation between day 8 VA trough
levels and antigen expression assessed by immunohistochemical staining, the VA trough level
on day 8 correlated with quantities of several KSHV mRNAs (Fig 1). The top 5% of KSHV
mRNAs were ordered by individual regression coefficients to build a multiple regression
model. Orf 48 (unknown function), orf8 (gB) and orf 22 (gH, two primers) correlated with VA
levels at day 8 with p≤0.02 (n = 12 patients).
Viral correlates in blood
Baseline and day 29 HIV RNA levels were available for 16 patients. Two patients (13%) had
detectable HIV viremia at baseline but not at day 29. One patient (6%) had HIV detected at
baseline and day 29. Thirteen patients (81%) had no detectable HIV at baseline or day 29. No
patients developed detectable HIV viremia during therapy. KSHV plasma and PBMC copy
numbers were available for 18 patients. No significant differences were observed between
baseline and either day 8 or day 29 copy numbers in either plasma or PBMC. A graphical
presentation of this data is in Fig. 1B. There was also no correlation between day 8 VA levels
and KSHV copy numbers in plasma or PBMC at day 8.
DISCUSSION
VA did not meet the pre-specified criteria for clinical response or KSHV lytic induction.
However, insofar as none of the patients discontinued VA because of toxicity, no patients
developed accelerated KS progression, and there were no detected adverse effects on HIV
viremia, we believe that the study offers reassurance about using VA in HIV-infected patients
with seizure or mood disorders who are seropositive for KSHV or have KS.
Whether induction of KSHV lytic infection would lead to the hoped-for therapeutic effect or,
as some have feared, lead to tumor progression remains unsettled. The finding that expression
of lytic viral mRNAs correlated with VA levels hints at the possibility that dose escalation
might lead to increased lytic expression. However, the modest changes seen and lack of
corresponding changes in either viral antigen expression assessed by immunohistochemistry
or viral DNA copy number in blood suggest that robust induction of lytic viral gene expression
may not be readily achievable and suggest consideration of alternative lytic activation
strategies. Vorinastat, 5-azacytidine and bortezomib have all been recognized as potent lytic
inducers in vitro[13] and may be more promising for future investigation.
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KSHV mRNA and DNA. A. Correlation of KSHV mRNA levels with VA trough levels after
treatment. The VA trough level is shown on the horizontal and relative mRNA levels (dCT)
on the vertical axes. The human housekeeping mRNA hprt, KSHV latent mRNA LANA,
KSHV orf22, which exhibited a linear trend (p≤0.05) and orf22 as measured by a second
independent primer are shown. Also shown are the linear regression lines and residuals. B.
KSHV DNA copy number in blood. Vertical bars corresponding to each patient are grouped
as pre-treatment, day 8, and day 29. The Y axis shows the log10 of KSHV copy number.
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Table 1
Selected Patient and Tumor Characteristics
Characteristic Number
Male Gender (%) 18 (100)
Age (Median, Range) 37 (29-60)
Absolute CD4 (Median, Range) 286 (82-1119)
HIV Load Undetectable (%) 13 (72)
50 lesions or greater (%) 9 (50)
No. of raised lesions (median) 6 (33)
No. of flat lesions (median) 13 (72)
Oral lesions present (%) 4 (22)
Tumor-associated edema (%) 10 (56)
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